Every new medicine that reaches an Australian pharmacy arrives with a small black triangle printed on its Product Information and Consumer Medicines Information leaflet. It is not a warning that something is wrong. It is a prompt: this drug is new, the safety picture is incomplete, and the Therapeutic Goods Administration wants to hear from you if something goes sideways. When people search for retatrutide side effects in Australia, this is the machinery that will eventually decide what we actually learn — and a study published this year suggests almost nobody here can recognise the symbol that drives it.

Retatrutide is Eli Lilly's investigational triple agonist, hitting GLP-1, GIP and glucagon receptors at once. It is not TGA-approved, and Lilly has signalled regulatory filings from 2027. So the black triangle conversation is a forward-looking one — but it's the right time to understand it, because the trial safety data is already public and it is more textured than "GI side effects, mostly mild".

Retatrutide side effects: what TRIUMPH-1 actually recorded

TRIUMPH-1 randomised 2,339 adults with obesity or overweight (without type 2 diabetes) across four arms — 4mg, 9mg, 12mg and placebo — over 80 weeks. Lilly reported average weight loss of 28.3% at 12mg on the treatment-regimen estimand, with 45.3% of participants losing 30% or more of body weight; AJMC reported an efficacy-estimand figure of up to 30.3%.

The safety column is where the detail sits. At 12mg, reported rates were roughly 42% nausea, 32% diarrhoea, 26% constipation and 25% vomiting — overwhelmingly mild to moderate, concentrated in the dose-escalation phase.

Two less-discussed signals are worth naming:

  • Dysesthesia — an unpleasant altered skin sensation — occurred in 5.1%, 12.3% and 12.5% of the 4mg, 9mg and 12mg groups versus 0.9% on placebo.
  • Urinary tract infections ran at 7.5%, 8.8% and 8.4% versus 5.3% on placebo.

Both were generally mild to moderate and mostly resolved on treatment. Separately, earlier phase 2 work flagged a transient heart-rate increase of roughly 6–9 beats per minute, which reporting has consistently described as warranting monitoring.

Then there's the number that matters most for real-world use: discontinuation due to adverse events rose with dose — 4.1%, 6.9% and 11.3% across the three arms, against 4.9% on placebo. Roughly one in nine people on the top dose stopped because of side effects. That is the tolerability trade-off sitting behind the headline efficacy. More on the full dataset on our clinical trials and safety pages.

Why 2,339 people is never the whole safety story

A phase 3 programme of this size can characterise common and moderately common events well. What it cannot do is reliably detect events that occur in, say, one in 10,000 users, or interactions that only emerge when a drug meets a messy, comorbid, polypharmacy population outside trial exclusion criteria.

That's the entire reason post-market surveillance exists. And Australia already has a live example in this exact drug class.

The TGA's black triangle — and Australia's awareness problem

The Black Triangle Scheme started in Australia at the beginning of 2018. A black triangle appears on the PI and CMI for new medicines — and older medicines approved for new uses — to remind prescribers, pharmacists and consumers to report suspected adverse events. For provisionally registered medicines, the TGA states the symbol appears for not less than five years. Tirzepatide (Mounjaro) carries one. Reports flow into the Database of Adverse Event Notifications (DAEN), which is publicly searchable.

Does it work? Sometimes, visibly. In December 2025 the TGA updated safety warnings across GLP-1 receptor agonists and tirzepatide — a class-wide precaution about suicidal thoughts or behaviours, plus revised contraception advice specific to Mounjaro — following a TGA review, international regulatory assessments, advice from the Advisory Committee on Medicines and analysis of DAEN data. That is post-market surveillance doing its job on drugs mechanistically adjacent to retatrutide.

The problem is the input side. A mixed-methods study led by researchers at the University of Adelaide, published in the British Journal of Clinical Pharmacology and reported by the ABC in June 2026, found more than 90% of consumers — and around half of health professionals — could not correctly identify the black triangle symbol. The authors suggested larger symbols or packaging stickers and targeted training for clinicians.

Australian implication: the safety picture of any new weight-loss medicine in this country is only as good as the reports Australians actually file. If retatrutide is eventually registered here, its black triangle period will be exactly the window in which rarer effects — the ones a 2,339-person trial can't see — either get detected or don't. Anyone reading up on retatrutide in Australia now is, realistically, reading up on a medicine whose Australian safety profile hasn't been written yet.

What this means if you're tracking retatrutide from Australia

Australia was one of the countries participating in the TRIUMPH registrational programme, so some of the data above includes Australian participants. But there is no Australian Product Information for retatrutide, no CMI, no black triangle and no DAEN entries, because there is no registered product. Everything we know about its side effects comes from sponsor-run trials — well conducted, peer-reviewed in parts, but not yet stress-tested by community use.

If you want the Australian regulatory and safety updates as they land, join the free updates list. Start with what retatrutide is if you're new to the mechanism.

FAQ

What are the side effects of retatrutide?

In the phase 3 TRIUMPH-1 trial, the most common side effects at the 12mg dose were nausea (~42%), diarrhoea (~32%), constipation (~26%) and vomiting (~25%), mostly mild to moderate and concentrated during dose escalation. Trials also recorded dysesthesia (12.5% at 12mg vs 0.9% placebo) and urinary tract infections, and discontinuation due to adverse events reached 11.3% at 12mg.

Is retatrutide approved in Australia?

No. Retatrutide is investigational and has no TGA registration, no Australian Product Information and no Consumer Medicines Information. Eli Lilly has indicated regulatory filings from 2027, and any Australian approval would follow its own TGA process and timeline.

What is the black triangle on Australian medicine leaflets?

It's the TGA's Black Triangle Scheme symbol, introduced in 2018, marking new medicines — or older medicines approved for new uses — as subject to additional safety monitoring. It prompts consumers and health professionals to report suspected adverse events, which feed the TGA's Database of Adverse Event Notifications.

Are retatrutide's side effects worse than Ozempic or Mounjaro?

There is no approved head-to-head safety comparison to settle that. Lilly has described retatrutide's safety profile as consistent with other GLP-1-containing medicines, with gastrointestinal effects most common, though retatrutide's trials also recorded dysesthesia at higher rates than placebo. TRIUMPH-5, a head-to-head against tirzepatide, has study completion estimated for December 2026.

Sources

This article is general information only and is not medical advice. Retatrutide is an investigational medicine and is not approved by the TGA. Speak to a qualified Australian health professional about your own circumstances. retatrutide.net.au is an independent information site and is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.